Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A modified fragment of human growth hormone (amino acids 177-191) originally developed as an anti-obesity agent. Targets fat metabolism without the growth-promoting effects of full HGH.
A dual GIP and GLP-1 receptor agonist developed by Eli Lilly. Represents the next generation of incretin-based therapies with potentially superior efficacy to semaglutide for weight loss.
Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) by mimicking the fat-reducing action of natural growth hormone without affecting blood sugar or tissue growth.
Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, producing enhanced insulin secretion, appetite suppression, and metabolic improvements beyond what single-agonist drugs achieve.
- Fat loss
- Metabolic health
- Body composition improvement
- Cartilage repair (emerging research)
- Weight management
- Type 2 diabetes treatment
- Metabolic health improvement
- Limited efficacy data in humans
- Injection site reactions
- Headaches
- Phase 2 trials showed modest results
- GI side effects (nausea, diarrhea, vomiting)
- Pancreatitis risk
- Injection site reactions
- Potential thyroid concerns
Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Previously reached Phase 2 clinical trials for obesity but was not pursued further by the original developer. Available through licensed 503A compounding pharmacies with a physician prescription.
FDA-approved as Mounjaro (diabetes, 2022) and Zepbound (weight management, 2023).
- AOD9604 - a novel anti-obesity drug
2001 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.